



## The Current Drug Discovery Landscape for Chagas Disease, HAT and Leishmaniasis: Target Validation and Chemotherapy

Guest Editor:

**Prof. Dr. Rafaela Salgado  
Ferreira**

Laboratório de Modelagem  
Molecular e Planejamento de  
Fármacos, Biochemistry and  
Immunology Department,  
Federal University of Minas Gerais  
(UFMG), Belo Horizonte 31270-  
901, Brazil

Deadline for manuscript  
submissions:

**closed (20 April 2024)**

### Message from the Guest Editor

Over the past years, public–private partnerships and academic consortiums have developed drug candidates and brought new therapies to the populations affected by NTDs. Examples from the past five years include the approval of Fexinidazole as a novel orally available for treating HAT caused by *T. b. gambiense*, and the successful treatment of patients with visceral leishmaniasis using a combination of miltefosine and paromomycin. Nevertheless, unmet needs remain. There are still no drugs which are effective in the chronic stage of Chagas disease, with very few drug candidates under consideration, and a similar scenario can be observed for cutaneous and mucocutaneous leishmaniasis.

Given the importance of developing novel therapies for Chagas disease, HAT, and leishmaniasis, we welcome authors to submit studies to this Special Issue and report on potential new drug candidates or contribute to the characterization and validation of molecular targets. Authors should contribute with their most recent results, or with reviews related to these topics. We look forward to receiving your contribution.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)